New nanodrug to treat sepsis by modulating the immune response
Bioactive immune-modulating nanodrug for sepsis treatment
This study is testing a new tiny drug that helps the immune system work better for people with sepsis, a serious condition caused by infections, by capturing harmful signals in the body to reduce inflammation and improve recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Upstate Medical University NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project ID | NIH-11076292 on NIH RePORTER |
What this research studies
This research focuses on developing a novel nanodrug designed to modulate the immune response in patients suffering from sepsis, a life-threatening condition caused by overwhelming infections. The approach involves using a specialized nanocarrier that can capture harmful inflammatory signals in the body, helping to restore normal immune function. By targeting specific inflammatory mediators, this treatment aims to reduce hyperinflammation and improve patient outcomes. The research will involve testing this nanodrug in preclinical models to assess its effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with sepsis or severe infections that lead to hyperinflammation.
Not a fit: Patients with mild infections or those who do not exhibit signs of sepsis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly improves survival rates and recovery for patients with sepsis.
How similar studies have performed: Previous research has shown promise in using nanotechnology for drug delivery and immune modulation, suggesting potential for success in this novel approach.
Where this research is happening
Syracuse, United States
- Upstate Medical University — Syracuse, United States (Active)
Researchers
- Principal investigator: Luo, Juntao — Upstate Medical University
- Study coordinator: Luo, Juntao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.